Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134781 | 0.90 | DDB1 (0.40) | DDB1CRBNHRH3PARP1SIGMAR1 | |
| SCHEMBL3981476 | 0.89 | MTNR1A (0.42) | ADRB2SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5435573 | 0.83 | SIGMAR1 (0.40) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4139977 | 0.83 | DDB1 (0.36) | DDB1CRBNADRB2MEN1ALDH1A1 | |
| SCHEMBL5433734 | 0.82 | SIGMAR1 (0.40) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5433728 | 0.82 | SIGMAR1 (0.40) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5433730 | 0.81 | SIGMAR1 (0.37) | SIGMAR1MEN1ALDH1A1KMT2ACNR2 | |
| SCHEMBL4174568 | 0.81 | KDM4E (0.34) | ADRB2SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4172529 | 0.78 | BRD4 (0.35) | ADRB2SIGMAR1MEN1ALDH1A1TSHR | |
| SCHEMBL4143498 | 0.78 | KDM4E (0.52) | DDB1CRBNHRH3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111760-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| EP-1824869-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050941-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111760-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | DDB1 3765/4885CRBN 3533/4885ADRB2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.